Literature DB >> 12828494

Consumer preference for dinoprostone vaginal gel using stated preference discrete choice modelling.

Susan Taylor1, Carol Armour.   

Abstract

OBJECTIVE: To assess consumer preference for two methods of induction of labour using stated preference discrete choice modelling. The methods of induction were artificial rupture of the membranes (ARM) plus oxytocin and dinoprostone (prostaglandin E(2)) vaginal gel, followed by oxytocin if necessary.
METHODS: Consumer preference was measured in terms of willingness to pay for each of the attributes. These attributes were the method of administration, place of care, length of time from induction to delivery, need for epidural anaesthetic, type of delivery and cost. Levels were assigned to each of the attributes. Pregnant women attending a public hospital antenatal clinic were asked to read a description of the two methods and then to choose between them in 18 different scenarios in which the levels of the attributes were varied.
RESULTS: Women were willing to pay 11 Australian dollars for a 1% reduction in the chance of needing oxytocin as well as the gel and 55 Australian dollars for every 1 hour reduction in the length of time from induction to delivery. For a 1% reduction in the chance of needing an epidural anaesthetic or Caesarean section, women expressed a willingness to pay of 20 Australian dollars and 90 Australian dollars, respectively. All estimates were obtained in 1998 and expressed in Australian dollars (1 Australian dollar = 0.63 US dollars).
CONCLUSION: Women valued the less invasive method of administration of the gel and the associated greater freedom of movement during labour. However, they valued the shorter time from induction to delivery associated with ARM plus oxytocin more highly. A policy which allows women access to the gel for up to two doses would accommodate this consumer preference.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828494     DOI: 10.2165/00019053-200321100-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  16 in total

Review 1.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation.

Authors:  M Ryan
Journal:  Soc Sci Med       Date:  1999-02       Impact factor: 4.634

3.  A role for conjoint analysis in technology assessment in health care?

Authors:  M Ryan
Journal:  Int J Technol Assess Health Care       Date:  1999       Impact factor: 2.188

4.  Assessing the economic value of a new antidepressant. A willingness-to-pay approach.

Authors:  B J O'Brien; S Novosel; G Torrance; D Streiner
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 5.  Economic evaluation in health care: is there a role for cost-benefit analysis?

Authors:  M Johannesson; B Jönsson
Journal:  Health Policy       Date:  1991-02       Impact factor: 2.980

6.  Willingness to pay for hormone replacement therapy.

Authors:  N Zethraeus
Journal:  Health Econ       Date:  1998-02       Impact factor: 3.046

7.  Using conjoint analysis to assess women's preferences for miscarriage management.

Authors:  M Ryan; J Hughes
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

8.  Agency in health care. Examining patients' preferences for attributes of the doctor-patient relationship.

Authors:  S Vick; A Scott
Journal:  J Health Econ       Date:  1998-10       Impact factor: 3.883

9.  Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach.

Authors:  P Davey; D Grainger; J MacMillan; N Rajan; M Aristides; M Dobson
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

10.  Measurement of consumer preference for treatments used to induce labour: a willingness-to-pay approach.

Authors:  Susan J. Taylor; Carol L. Armour
Journal:  Health Expect       Date:  2000-09       Impact factor: 3.377

View more
  5 in total

1.  Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D.

Authors:  Julie Ratcliffe; Terry Flynn; Frances Terlich; Katherine Stevens; John Brazier; Michael Sawyer
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

2.  Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods.

Authors:  Diego F Ossa; Andrew Briggs; Emma McIntosh; Warren Cowell; Tim Littlewood; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Measuring consumer preference for models of diabetes care delivered by pharmacists.

Authors:  Susan Taylor; Fleur Hourihan; Ines Krass; Carol Armour
Journal:  Pharm Pract (Granada)       Date:  2009-03-15

4.  Protocol for the immediate delivery versus expectant care of women with preterm prelabour rupture of the membranes close to term (PPROMT) Trial [ISRCTN44485060].

Authors:  Jonathan M Morris; Christine L Roberts; Caroline A Crowther; Sarah L Buchanan; David J Henderson-Smart; Glenn Salkeld
Journal:  BMC Pregnancy Childbirth       Date:  2006-03-23       Impact factor: 3.007

5.  Double balloon catheters: A promising tool for induction of labor in multiparous women with unfavorable cervices

Authors:  Fırat Tülek; Ali Gemici; Feride Söylemez
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.